Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral collagen tripeptide is a bioactive peptide-based health supplement being developed by Chongqing Fujin Biomedical for a range of age-related conditions. Unlike standard collagen hydrolysates, collagen tripeptides are composed of three amino acids (typically following a Gly-X-Y sequence) that exhibit high bioavailability and can be absorbed directly into the systemic circulation. The product is designed to support skin and connective tissue health by promoting the proliferation of dermal papilla cells, increasing bone density, and reducing joint inflammation. Additionally, it is intended to influence mitochondrial function to address sarcopenia and general physiological aging. The program is currently in the preclinical stage, with the developer having completed laboratory synthesis and scale-up production, and is registered in Hainan while planning for third-party human clinical verification.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oral collagen tripeptide.